Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 4

Evaluation of Factors Influencing Survival in Metastatic Renal Cell Cancer

Pages
469–475
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Factors determined to be significant in univariate analysis were assessed using multivariate analysis and the results identified a tumor size larger than 6 cm (p= 0.032), ECOG PS ≥2 (p 6cm, hemoglobin ≤13gr/dL, serum albumin ≤3,6 gr/dL and ECOG PS ≥2 as factors influencing the prognosis unfavorably in mRCC patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The use of prognostic factors that can correctly predict the clinical outcomes of patients with mRCC has particular importance for individualized risk assessment.
📊
Key Findings & Data:Methods: Eighty-six patients who were diagnosed with de-novo metastatic renal cell cancer or developed metastasis during follow-up between January 2007-January 2020 were included and their files were retrospectively evaluated.
💡
Conclusion & Impact:Results: Factors determined to be significant in univariate analysis were assessed using multivariate analysis and the results identified a tumor size larger than 6 cm (p= 0.032), ECOG PS ≥2 (p 6cm, hemoglobin ≤13gr/dL, serum albumin ≤3,6 gr/dL and ECOG PS ≥2 as factors influencing the prognosis unfavorably in mRCC patients.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The use of prognostic factors that can correctly predict the clinical outcomes of patients with mRCC has particular importance for individualized risk assessment. In this study, we aimed to address the prognostic factors in mRCC patients. Methods: Eighty-six patients who were diagnosed with de-novo metastatic renal cell cancer or developed metastasis during follow-up between January 2007-January 2020 were included and their files were retrospectively evaluated. From patient files; demographic characteristics [age, gender, EGOC PS (Eastern Cooperative Oncology Group perfor- mance status), tumor localization, tumor size, metastasis status, metastatic sites], histopathological characteristics and laboratory tests (hemoglobin, serum albumin, lactate dehydrogenase), treatments they received were recorded. Results: Factors determined to be significant in univariate analysis were assessed using multivariate analysis and the results identified a tumor size larger than 6 cm (p= 0.032), ECOG PS ≥2 (p 6cm, hemoglobin ≤13gr/dL, serum albumin ≤3,6 gr/dL and ECOG PS ≥2 as factors influencing the prognosis unfavorably in mRCC patients.

🔖

Cite This Article

Kaplan, M. A., Oruc, Z., Isikdogan, A., Ebinc, S., Urakci, Z., Kalkan, Z., Ileri, S., Tunc, S., Kucukoner, M. (2022). Evaluation of Factors Influencing Survival in Metastatic Renal Cell Cancer. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 4, 469–475. https://ajindex.com/articles/508582

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cheng G, Liu D, Liang H, Yang H, Chen K, Zhang X. A cluster of long noncoding RNAs exhibit diagnostic and prognostic val-ues in renal cell carcinoma. Aging 2019;11:9597–615
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci- dence and mortality worldwide for 36 cancers in 185 coun- tries. CA Cancer J Clin. 2018 Nov;68(6):394-424
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Can- cer J Clin 2018;68:7–30
  4. Sun M, Choueiri TK. Kidney cancer: Recurrence in renal cell carcinoma: The work is not done. Nat Rev Urol 2016;13:246–7
  5. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldeg- run AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratifica- tion system. J Urol 2005;174:466–72
  6. Abe H, Kamai T. Recent advances in the treatment of meta- static renal cell carcinoma. Int J Urol 2013;20:944–55
  7. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, et al. A review of integrated staging systems for renal cell carci- noma. Eur Urol 2012;62:303–14
  8. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, et al. Out- comes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014;25:149–54
  9. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endo- thelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009;27:5794–9
  10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Inter- feron-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–96
  11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30
  12. Kroeger N, Zimmermann U, Burchardt M, Pantuck AJ. Prog- nostication in localised renal cell carcinoma. Lancet Oncol 2015;16:603–4
  13. Song J, Song F, Liu K, Zhang W, Luo R, Tang Y, et al. Multi-omics analysis reveals epithelial-mesenchymal transition-related gene FOXM1 as a novel prognostic biomarker in clear cell re- nal carcinoma. Aging 2019;11:10316– 37
  14. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carci- noma: A con